AMA opposes BTC class
This article was originally published in The Tan Sheet
Executive SummaryThe American Medical Association reaffirms its stance against a formal behind-the-counter drug class under consideration by FDA (see story, p. 5). A resolution introduced by AMA's Michigan delegation cites BTC prescribing as potentially "out of the realm of a pharmacist's training," which "might affect patient safety and quality of care." The AMA House of Delegates, which held its annual meeting June 15, did not pass the resolution because the association in 1984 adopted a policy opposing "a third transitional class of drugs." AMA questions FDA's authority to create a third drug class (1"The Tan Sheet" Nov. 19, 2007, p. 4)...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.